Request Information

News

Media coverage of Auris Health

Contact us

Auris Health Announces $220 Million Growth Financing

Funds Will Be Used to Advance Commercialization and Development of Next-Generation Robotic Interventional Technology

REDWOOD CITY, Calif. – November 28, 2018 – Auris Health, Inc. today announced the close of a $220 million equity financing led by Partner Fund Management. New investors Wellington Management, D1 Capital Partners and Senator Investment Group and existing investors including Mithril Capital, Lux Capital and Viking Global Investors also participated in the round. The company has now raised more than $700 million to date. Funding will be used to advance the commercialization of the company’s Monarch™ Platform and the development of next-generation robotic interventional technology.

Continue Reading

Auris Health Announces Results From New Study of Monarch™ Platform Presented in Late-Breaking Session at CHEST 2018

ACCESS Study Demonstrates Ability of Monarch to Successfully Reach Nodules and Biopsy Tissue

REDWOOD CITY, Calif. & SAN ANTONIO--Auris Health, Inc., today announced the results of a study designed to test the ability of the Monarch™ Platform, the first FDA-cleared robotic platform for diagnostic and therapeutic bronchoscopic procedures, to successfully access nodules in the lung.

Continue Reading

Auris Health Announces Collaboration with Ethicon to Enable Bronchoscopic Ablation of Lesions in the Lung

Companies Collaborate to Integrate the NeuWave™ Flexible Microwave Ablation Technology with Auris’s Monarch™ Platform for Robotic Bronchoscopy

REDWOOD CITY, CALIF. – May 15, 2018 –Auris Health, Inc. today announced that the company has entered into a cooperative development and commercialization agreement with NeuWave™ Medical, Inc., a subsidiary of Ethicon, Inc., and part of the Johnson & Johnson Medical Devices Companies, with the goal of enabling robotically assisted bronchoscopic ablation of lesions in the lung.

Continue Reading

Auris Health Unveils the FDA-Cleared Monarch Platform, Ushering in a New Era of Medical Intervention

Company’s First Application of Its Innovative Flexible Robotics Platform Is Bronchoscopy

Redwood City, Calif. – March 23, 2018 – Auris Health, Inc. ("Auris Health"), formerly known as Auris Surgical Robotics, Inc., today announced U.S. Food and Drug Administration (FDA) clearance of the company’s Monarch™ Platform, ushering in a new era of medical intervention.

Continue Reading